Cargando…

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas

Cabergoline (CAB) is the first choice for treatment of prolactinoma and the most common subtype of pituitary adenoma. However, drug resistance and lack of effectiveness in other pituitary tumor types remain clinical challenges to this treatment. Brusatol (BT) is known to inhibit cell growth and prom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zerui, Xu, Yunqiu, Xu, Jiadong, Lu, Jianglong, Cai, Lin, Li, Qun, Wang, Chengde, Su, Zhipeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221873/ https://www.ncbi.nlm.nih.gov/pubmed/34221237 http://dx.doi.org/10.1155/2021/6696015

Ejemplares similares

Thyrotropin-Secreting Pituitary Adenoma Successfully Treated With Cabergoline
por: Saand, Aisha R, et al.
Publicado: (2021)

Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis
por: Lu, Jianglong, et al.
Publicado: (2021)

Treatment of Postsurgical Clinically Nonfunctioning Pituitary Adenomas Remnants With Cabergoline
por: Vieira, Marina C M, et al.
Publicado: (2021)

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline
por: Bozkirli, Emre, et al.
Publicado: (2013)

NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas
por: Jian, Fangfang, et al.
Publicado: (2021)

Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
por: Vargas-Ortega, Guadalupe, et al.
Publicado: (2022)

Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012)

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1
por: Dai, Zhang’an, et al.
Publicado: (2021)

PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline
por: Begalli, Federica, et al.
Publicado: (2022)

Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018)

Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients
por: Ceccato, Filippo, et al.
Publicado: (2021)

A Quantified Risk-Scoring System for the Recurrence of Meningiomas: Results From a Retrospective Study of 392 Patients
por: Zhu, Zhangzhang, et al.
Publicado: (2020)

Cabergoline-induced Mania in a Patient of Pituitary Microadenoma
por: Mohapatra, Satyakam, et al.
Publicado: (2017)

A Multielement Prognostic Nomogram Based on a Peripheral Blood Test, Conventional MRI and Clinical Factors for Glioblastoma
por: Rao, Changjun, et al.
Publicado: (2022)

Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Pirchio, Rosa, et al.
Publicado: (2021)

Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019)

Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe
por: Singh, Pratibha, et al.
Publicado: (2011)

SAT-272 Pituitary Macroadenoma Co-Secreting TSH and PRL Responsive to Cabergoline
por: Tirumalasetty, Saritha, et al.
Publicado: (2020)

The toxic effects and possible mechanisms of Brusatol on mouse oocytes
por: Ma, Rujun, et al.
Publicado: (2017)

Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline
por: Walia, Rama, et al.
Publicado: (2011)

SAT-246 A Case of Cabergoline Induced Pituitary Apoplexy in a Patient with Prolactinoma
por: Ahuja, Ashim
Publicado: (2020)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018)

Analysis of operative efficacy for giant pituitary adenoma
por: Wang, Shousen, et al.
Publicado: (2014)

Pituitary Adenoma Surgery Survey: Neurosurgical Centers and Pituitary Adenomas
por: Netuka, David, et al.
Publicado: (2022)

Pituitary Crooke Cell Adenoma: Two Cases of an Aggressive Pituitary Adenoma
por: Taiwo, Adeyinka, et al.
Publicado: (2023)

Brusatol: A potential anti-tumor quassinoid from Brucea javanica
por: Yu, Xiao-qi, et al.
Publicado: (2020)

Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety
por: Castro, Douglas G, et al.
Publicado: (2010)

Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
por: Lin, Shaojian, et al.
Publicado: (2022)

Cytology of Pituitary Adenomas
por: Doniach, I.
Publicado: (1972)

The Epigenomics of Pituitary Adenoma
por: Hauser, Blake M., et al.
Publicado: (2019)

The Genetics of Pituitary Adenomas
por: Tatsi, Christina, et al.
Publicado: (2019)

Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
por: Sun, Xiaohui, et al.
Publicado: (2016)

Abstract 94: Efficacy of cabergoline treatment in men with giant prolactinomas
Publicado: (2022)

MicroRNAs in Human Pituitary Adenomas
por: Li, Xu-Hui, et al.
Publicado: (2014)

The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence
por: Kim, Jee Soon, et al.
Publicado: (2016)

Pituitary adenoma with gangliocytoma: Report of two cases
por: CHEN, DANQI, et al.
Publicado: (2014)

Remission in Cushing disease with cabergoline
por: Gopal, Raju, et al.
Publicado: (2008)

Endoscopic Trans-Sphenoidal surgery; Efficacy and response in Pituitary Adenoma
por: Rehman, Lal, et al.
Publicado: (2018)

Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell
por: Su, Zhipeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r0k74k6b21akpgrhl4c4m5qkli